Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | CCR3 | P51677 | 2/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592322 | 0.91 | PRKAA2 (0.35) | KCNH2MCHR1BACE1KAT2BFAAH | |
| SCHEMBL594333 | 0.91 | FAAH (0.35) | KCNH2MCHR1BACE1KAT2BFAAH | |
| SCHEMBL10183012 | 0.91 | BACE1 (0.34) | KCNH2MCHR1BACE1KAT2BFAAH | |
| SCHEMBL593414 | 0.91 | POLB (0.34) | KCNH2MCHR1BACE1CCR3KAT2B | |
| SCHEMBL593704 | 0.90 | ALDH1A1 (0.39) | KCNH2BACE1FAAH | |
| SCHEMBL593222 | 0.90 | JAK2 (0.34) | KCNH2MCHR1BACE1KAT2BFAAH | |
| SCHEMBL8268428 | 0.90 | ROCK2 (0.34) | KCNH2MCHR1BACE1KAT2BFAAH | |
| SCHEMBL593626 | 0.90 | KAT2B (0.38) | KCNH2MCHR1BACE1KAT2B | |
| SCHEMBL594013 | 0.90 | FAAH (0.39) | KCNH2MCHR1BACE1KAT2BFAAH | |
| SCHEMBL594170 | 0.89 | BACE1 (0.36) | KCNH2MCHR1BACE1KAT2BFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197571-A1 | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzheimer' s disease | BACE1, BACE2, APP | KCNH2 1880/4885MCHR1 4418/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.